Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CPA3 | P15088 | 3/20 | 0.58 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.54 |
| ▸ | CPA1 | P15085 | 7/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15247515 | 1.00 | FOLH1 (0.64) | FOLH1CYP1A2CPA3TBXAS1CPA1 | |
| SCHEMBL23833831 | 0.95 | FOLH1 (0.62) | FOLH1CYP1A2CPA3TBXAS1CPA1 | |
| SCHEMBL15247509 | 0.90 | CYP1A2 (0.63) | FOLH1CYP1A2CPA3TBXAS1CPA1 | |
| SCHEMBL12418042 | 0.90 | CYP1A2 (0.63) | FOLH1CYP1A2CPA3TBXAS1CPA1 | |
| SCHEMBL11664393 | 0.84 | FOLH1 (0.79) | FOLH1CYP1A2CPA3CPA1CPB1 | |
| SCHEMBL23833858 | 0.82 | REN (0.44) | FOLH1CYP1A2CPA3TBXAS1 | |
| SCHEMBL9349685 | 0.81 | FOLH1 (0.70) | FOLH1CYP1A2CPA3CPA1CPB1 | |
| SCHEMBL6724759 | 0.80 | CYP1A2 (0.83) | FOLH1CYP1A2CPA3CPA1CPB1 | |
| SCHEMBL12494233 | 0.80 | CYP1A2 (0.83) | FOLH1CYP1A2CPA3CPA1CPB1 | |
| SCHEMBL19821208 | 0.80 | CYP1A2 (0.83) | FOLH1CYP1A2CPA3CPA1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2021188620-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188620-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-8530456-B2 | Sonic hedgehog modulators | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110172233-A1 | SONIC HEDGEHOG MODULATORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2011-07-14 | — | — | US | disclosed |
| US-20110172233-A1 | SONIC HEDGEHOG MODULATORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2011-07-14 | — | — | US | disclosed |
| WO-2009132032-A2 | SONIC HEDGEHOG MODULATORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | ASNS, GLUL, GNMT | FOLH1 485/4885CYP1A2 4091/4885CPA3 2953/4885 |
| US-20110172233-A1 | SONIC HEDGEHOG MODULATORS | SHH, GLI1, SMO | FOLH1 2179/4885CYP1A2 4773/4885CPA3 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.